COVID-19 Human IgG PharmaGenie ELISA Kit (NP/S1 RBD) (SBRS1730)

The COVID-19 Human IgG PharmaGenie ELISA Kit from Assay Genie is built around an indirect immunoassay principle, using microplate wells pre-coated with recombinant SARS-CoV-2 antigens corresponding to the nucleocapsid protein and the spike protein S1 receptor-binding domain. The assay enables qualitative and semi-quantitative detection of human IgG class antibodies against these viral antigens across multiple specimen types, including venous plasma, saliva, serum, and dried blood collected on filter paper, supporting field-friendly dried blood spot workflows in remote or decentralized settings.

Because IgG responses persist for months after infection or vaccination, this kit supports seroprevalence surveys, post-infection follow-up studies, and immunogenicity monitoring following SARS-CoV-2 vaccination campaigns. The detection reagent is an anti-human IgG HRP conjugate paired with a chromogenic substrate read on a standard microplate reader, with the protocol calling for 100 µL of sample per well, delivering a practical workflow for laboratories running population-scale screening.

Each kit provides reagents sufficient for 96 determinations, including pre-coated microplate wells, calibrators, positive and negative controls, wash buffer, conjugate, substrate solution, and stop reagent. Component vials should be refrigerated and protected from light; consult the enclosed protocol for storage conditions and stability of opened reagents. For research use only.